The increase in the utilization of monoclonal antibodies as therapeutics over the past two decades has been remarkable, with over 80 mAbs approved for use. The quick pace of clinical studies and ...
Existing monoclonal antibody development technologies, such as hybridoma technology, suffer from a loss of diversity due to cell fusion efficiency, and phage display technology creates antibodies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback